Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) and Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.
Profitability
This table compares Oruka Therapeutics and Achieve Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Oruka Therapeutics | N/A | -24.96% | -21.22% |
| Achieve Life Sciences | N/A | -108.30% | -65.20% |
Earnings and Valuation
This table compares Oruka Therapeutics and Achieve Life Sciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Oruka Therapeutics | N/A | N/A | -$5.34 million | ($5.79) | -2.09 |
| Achieve Life Sciences | N/A | N/A | -$29.82 million | ($1.23) | -2.28 |
Risk & Volatility
Oruka Therapeutics has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.67, meaning that its share price is 67% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Oruka Therapeutics and Achieve Life Sciences, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Oruka Therapeutics | 0 | 0 | 7 | 2 | 3.22 |
| Achieve Life Sciences | 0 | 0 | 3 | 2 | 3.40 |
Oruka Therapeutics presently has a consensus target price of $39.86, suggesting a potential upside of 229.40%. Achieve Life Sciences has a consensus target price of $15.75, suggesting a potential upside of 460.50%. Given Achieve Life Sciences’ stronger consensus rating and higher probable upside, analysts plainly believe Achieve Life Sciences is more favorable than Oruka Therapeutics.
Institutional & Insider Ownership
56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 22.7% of Oruka Therapeutics shares are owned by company insiders. Comparatively, 2.0% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Oruka Therapeutics beats Achieve Life Sciences on 7 of the 11 factors compared between the two stocks.
About Oruka Therapeutics
Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
